Neurometrix Inc shares had a trading volume of 82K by the end of trading on Tuesday. Overall, volume was up 108.54% over the stocks normal daily volume.
Traders are a little more bearish on shares of Neurometrix Inc lately considering the change in short interest. The company experienced a rise in short interest from September 29, 2017 to October 13, 2017 of 26.04%. Short interest increased from 77,127 to 97,212 over that period. Days to cover decreased from 8.0 to 1.0 and the percentage of shorted shares is 0.04% as of October 13.
Here is a rundown on some insider market activity for Neurometrix Inc (NASDAQ:NURO). Thomas T. Higgins, Sr VP bought $4,250 worth of shares at an average price of $1.70 on October 25th. That brings the Sr VP’s holdings to $35,637 as reported to the SEC. Thomas T. Higgins, Sr VP disclosed the purchase of 2,500 shares of (NURO). The shares were bought on October 23rd for an average price of $1.77. The Sr VP now owns $32,680 of the stock according to the SEC filing.
These firms have modified their investment in NURO. As of the end of the quarter Renaissance Technologies LLC had acquired a total of 28,400 shares growing its holdings by 30.3%. The value of the company’s investment in Neurometrix Inc went from $69,000 to $76,000 a change of $7,000 quarter over quarter. Kcg Holdings, Inc. expanded its holdings by buying 122,002 shares an increase of 617.8% as of 03/31/2017. Kcg Holdings, Inc. claims 141,750 shares worth $88,000. The value of the position overall is up by 183.9%.
Manufacturers Life Insurance Company, The grew its ownership by buying 26,351 shares an increase of 12,854.1% in the quarter. Manufacturers Life Insurance Company, The now holds 26,556 shares valued at $16,000. The total value of its holdings increased inf%. As of quarter end Sabby Management, LLC had bought 135,836 shares growing its stake by 81.7%. The value of the investment in (NURO) increased from $123,000 to $187,000 a change of 52.0% quarter to quarter.
October 20 investment analysts at HC Wainwright maintained a company rating of “Buy” targeting a price of $3.00.
The company is trading up since yesterday’s close of 1.66. The most current P/E ratio is N/A and the market value is 3.99M. In the latest earnings report the EPS was $-17.01 with 2.35M shares currently outstanding.
NeuroMetrix, Inc., launched on April 25, 2001, is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is involved in the sale of medical equipment, and consumables and accessories. It is involved in designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. Its business is fully integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. Its products are sold in the United States and selected overseas markets. The Company has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products consist of a medical device used in conjunction with a consumable electrode or biosensor. Other accessories and consumables are also available to customers. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck..